Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of $292.53 billion. The enterprise value is $334.25 billion.
| Market Cap | 292.53B |
| Enterprise Value | 334.25B |
Important Dates
The last earnings date was Tuesday, July 21, 2026, before market open.
| Earnings Date | Jul 21, 2026 |
| Ex-Dividend Date | Mar 11, 2026 |
Share Statistics
Novartis AG has 1.90 billion shares outstanding. The number of shares has decreased by -3.34% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.90B |
| Shares Change (YoY) | -3.34% |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 37.31% |
| Float | 1.86B |
Valuation Ratios
The trailing PE ratio is 22.93 and the forward PE ratio is 16.67.
| PE Ratio | 22.93 |
| Forward PE | 16.67 |
| PS Ratio | 5.16 |
| Forward PS | 5.04 |
| PB Ratio | 6.97 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 17.45 |
| P/OCF Ratio | 15.90 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.83, with an EV/FCF ratio of 19.94.
| EV / Earnings | 26.20 |
| EV / Sales | 5.90 |
| EV / EBITDA | 14.83 |
| EV / EBIT | 19.54 |
| EV / FCF | 19.94 |
Financial Position
The company has a current ratio of 0.86, with a Debt / Equity ratio of 1.17.
| Current Ratio | 0.86 |
| Quick Ratio | 0.55 |
| Debt / Equity | 1.17 |
| Debt / EBITDA | 2.17 |
| Debt / FCF | 2.92 |
| Interest Coverage | 12.30 |
Financial Efficiency
Return on equity (ROE) is 30.35% and return on invested capital (ROIC) is 18.78%.
| Return on Equity (ROE) | 30.35% |
| Return on Assets (ROA) | 10.25% |
| Return on Invested Capital (ROIC) | 18.78% |
| Return on Capital Employed (ROCE) | 18.94% |
| Weighted Average Cost of Capital (WACC) | 6.31% |
| Revenue Per Employee | $753,225 |
| Profits Per Employee | $169,490 |
| Employee Count | 75,267 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, Novartis AG has paid $2.78 billion in taxes.
| Income Tax | 2.78B |
| Effective Tax Rate | 17.88% |
Stock Price Statistics
The stock price has increased by +33.19% in the last 52 weeks. The beta is 0.50, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | +33.19% |
| 50-Day Moving Average | 152.66 |
| 200-Day Moving Average | 146.50 |
| Relative Strength Index (RSI) | 48.11 |
| Average Volume (20 Days) | 1,753,618 |
Short Selling Information
The latest short interest is 5.71 million, so 0.30% of the outstanding shares have been sold short.
| Short Interest | 5.71M |
| Short Previous Month | 5.25M |
| Short % of Shares Out | 0.30% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.66 |
Income Statement
In the last 12 months, Novartis AG had revenue of $56.69 billion and earned $12.76 billion in profits. Earnings per share was $6.61.
| Revenue | 56.69B |
| Gross Profit | 42.51B |
| Operating Income | 18.57B |
| Pretax Income | 15.52B |
| Net Income | 12.76B |
| EBITDA | 22.54B |
| EBIT | 17.10B |
| Earnings Per Share (EPS) | $6.61 |
Balance Sheet
The company has $7.62 billion in cash and $49.01 billion in debt, with a net cash position of -$41.40 billion or -$21.78 per share.
| Cash & Cash Equivalents | 7.62B |
| Total Debt | 49.01B |
| Net Cash | -41.40B |
| Net Cash Per Share | -$21.78 |
| Equity (Book Value) | 41.95B |
| Book Value Per Share | 21.86 |
| Working Capital | -4.40B |
Cash Flow
In the last 12 months, operating cash flow was $18.39 billion and capital expenditures -$1.63 billion, giving a free cash flow of $16.76 billion.
| Operating Cash Flow | 18.39B |
| Capital Expenditures | -1.63B |
| Depreciation & Amortization | 4.53B |
| Net Borrowing | 16.45B |
| Free Cash Flow | 16.76B |
| FCF Per Share | $8.82 |
Margins
Gross margin is 74.98%, with operating and profit margins of 32.75% and 22.50%.
| Gross Margin | 74.98% |
| Operating Margin | 32.75% |
| Pretax Margin | 27.38% |
| Profit Margin | 22.50% |
| EBITDA Margin | 39.77% |
| EBIT Margin | 30.17% |
| FCF Margin | 29.57% |
Dividends & Yields
This stock pays an annual dividend of $3.08, which amounts to a dividend yield of 2.01%.
| Dividend Per Share | $3.08 |
| Dividend Yield | 2.01% |
| Dividend Growth (YoY) | 18.68% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 46.58% |
| Buyback Yield | 3.34% |
| Shareholder Yield | 5.34% |
| Earnings Yield | 4.36% |
| FCF Yield | 5.73% |
Analyst Forecast
The average price target for Novartis AG is $155.37, which is 1.44% higher than the current price. The consensus rating is "Hold".
| Price Target | $155.37 |
| Price Target Difference | 1.44% |
| Analyst Consensus | Hold |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 4.67% |
| EPS Growth Forecast (3Y) | 6.44% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 11, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | May 11, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novartis AG has an Altman Z-Score of 3.36 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.36 |
| Piotroski F-Score | 5 |